SCHEMBL3600523

SCHEMBL3600523

CN(C)CCOc1ccc(N(S)C(N)=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
HRH3 Q9Y5N1 3/20 0.49
KDM4E B2RXH2 4/20 0.48
POLB P06746 1/20 0.48
LTA4H P09960 2/20 0.47
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
CHEK1 O14757 1/20 0.44
MAPT P10636 1/20 0.43
ESR1 P03372 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711589 0.83 TAAR1 (0.44) LTA4HSMN1; SMN2CYP1A2CYP3A4ESR1
SCHEMBL3428654 0.82 TP53 (0.53) LTA4HMAPT
SCHEMBL10548607 0.81 PARP10 (0.56) POLBALDH1A1CYP1A2MAPT
SCHEMBL3983563 0.79 PARP10 (0.51)
SCHEMBL3018123 0.78 PARP10 (0.62) KEAP1NFE2L2HRH3KDM4EPOLB
SCHEMBL4991366 0.77 HDAC1 (0.50) LTA4H
SCHEMBL6680643 0.76 HRH3 (0.50) HRH3ACHE
SCHEMBL526027 0.75 CA1 (0.52) SMN1; SMN2MAPT
SCHEMBL6837559 0.75 HRH3 (0.51) KEAP1NFE2L2HRH3KDM4EPOLB
SCHEMBL56046 0.75 HRH3 (0.63) KEAP1NFE2L2HRH3KDM4ELTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687285-B1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-05 EP disclosed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US disclosed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US disclosed
EP-1687285-A1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS Novartis AG (CH) 2006-08-09 EP disclosed
WO-2005047273-A1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors FLT3, FLT1, FLT4 KEAP1 2664/4885NFE2L2 2952/4885HRH3 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.